Uveitis in spondyloarthritis: current possibilities of anti-inflammatory therapy
https://doi.org/10.47360/1995-4484-2025-146-157
Abstract
Uveitis is a common extra-skeletal manifestation of ankylosing spondylitis (AS) and other spondyloarthritis (SpA). The recurrent course of uveitis in SpA contributes to the development of complications affecting vision. Timely treatment of uveitis exacerbation and prevention of relapses is an important component of SpA management. The article discusses approaches to modern anti-inflammatory therapy of uveitis in SрA, including traditional and targeted drugs. The data from clinical studies on the effect of various treatment regimens on the course of uveitis in SpA are presented, as well as a comparative assessment of the effectiveness of biologic and targeted synthetic drugs.
About the Authors
A. A. Godzenko
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation;
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Alla A. Godzenko
125993, Moscow, Barrikadnaya str., 2/1, building 1,
115522, Moscow, Kashirskoye Highway, 34A
N. L. Sheremet
M.M. Krasnov Research Institute of Eye Diseases
Russian Federation
Russian Federation
Natalia L. Sheremet
119021, Moscow, Rossolimo str., 11
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Evgeny L. Nasonov
115522, Moscow, Kashirskoye Highway, 34A
References
1. Non-infectious uveitis: Clinical guidelines of the Association of Ophthalmologists, Society of Ophthalmologists of Russia. 2024 (In Russ.). URL: https://cr.minzdrav.gov.ru/ (Accessed: 12 July 2024).
2. Tsirouki T, Dastiridou A, Symeonidis C, Tounakaki O, Brazitikou I, Ocul Immunol Inflamm. 2018;26(1):2-16. doi: 10.1080/09273948.2016.1196713
3. Standardization of Uveitis Nomenclature (SUN) Working Group. Development of classification criteria for the uveitides. Am J Ophthalmol. 2021;228:96-105. doi: 10.1016/j.ajo.2021.03.061
4. Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80(12):1511-1521. doi: 10.1136/annrheumdis-2021-221035
5. Gordon H, Burisch J, Ellul P, Karmiris K, Katsanos K, Allocca M, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18(1):1-37. doi: 10.1093/ecco-jcc/jjad108
6. Sharma SM, Jackson D. Uveitis and spondyloarthropathies. Best Pract Res Clin Rheumatol. 2017;31(6):846-862. doi: 10.1016/j.berh.2018.08.002
7. D’Ambrosio EM, La Cava M, Tortorella P, Gharbiya M, Campanella M, Iannetti L. Clinical features and complications of the HLA-B27-associated acute anterior uveitis: A metanalysis. Semin Ophthalmol. 2017;32(6):689-701. doi: 0.3109/08820538.2016.1170158
8. Bernal-Morales C, Ramanan AV, Pavesio C. Use of immunomodulators in non-infectious uveitis: Lights and shadows. Eye (Lond). 2024;38(17):3231-3242. doi: 10.1038/s41433-024-03294-9
9. Podryadnova MV, Balabanova RM, Urumova MM, Erdes ShF. Correlation between clinical characteristics of ankylosing spondylitis and work capacity and productivity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(5):513-519 (In Russ.). doi: 10.14412/1995-4484-2014-513-519
10. Morozov VI. A hematoophthalmic barrier: Structural and functional features. Russian Ophthalmological Journal. 2017;10(4):68-72 (In Russ.). doi: 10.21516/2072-0076-2017-10-4-68-72
11. Fiorelli VM, Bhat P, Foster CS. Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm. 2010;18(2):116-120. doi: 10.3109/09273941003587558
12. Muñoz-Fernández S, Hidalgo V, Fernández-Melón J, Schlincker A, Bonilla G, Ruiz-Sancho D, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol. 2003;30(6):1277-1279.
13. Benitez-del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond). 2000;14(Pt 3A):340-343. doi: 10.1038/eye.2000.84
14. Godzenko AA, Bochkova AG, Rumyantseva OA, Razumova IYu, Badokin VV, Erdes ShF. Course of uveitis in patients with ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(Suppl 1):33-37 (In Russ.). doi: 10.14412/1995-4484-2016-1S-33-37
15. Zu Hoerste MM, Walscheid K, Tappeiner C, Zurek-Imhoff B, Heinz C, Heiligenhaus A. The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: Results from a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol. 2018;256(10):1985-1992. doi: 10.1007/s00417-018-4082-x
16. Bouzid N, Jamilloux Y, Chapurlat R, Pradat P, De Parisot A, Kodjikian L, et al. Impact of systemic treatments on the course of HLA-B27-associated uveitis: A retrospective study of 101 patients. PLoS One. 2020;15(3):e0230560. doi: 10.1371/journal.pone.0230560
17. Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808-818. doi: 10.1136/annrheumdis-2018-213225
18. Kaçmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576-584. doi: 10.1016/j.ophtha.2009.08.010
19. Poizeau F, Leducq S, Fardet L, Beylot-Barry M, Chaby G, Chastagner M, et al.; Psoriasis Research Group (GRPso) and the Centre of Evidence of the French Society of Dermatology. Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm. Ann Dermatol Venereol. 2024;151(3):103287. doi: 10.1016/j.annder.2024.103287
20. Gaidukova IZ, Rebrov AP, Lapshina SA, Otteva EN, Dubinina TV, Badokin VV, et al. Use of nonsteroidal anti-inflammatory drugs and biological agents for the treatment of axial spondyloarthritides. Recommendations of the Spondyloarthritis Study Group of Experts, All-Russian Public Organization «The Association of Rheumatology of Russia». Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(5):474-484 (In Russ.). doi: 10.14412/1995-4484-2017-474-484
21. Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19-34. doi: 10.1136/ard-2022-223296
22. Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R Jr, Brézin AP, Chee SP, et al.; Fundamentals of Care for Uveitis International Consensus Group. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology. 2018;125(5):757-773. doi: 10.1016/j.ophtha.2017.11.017
23. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52(8):2447-2451. doi: 10.1002/art.21197
24. Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Ann Rheum Dis. 2009;68(5):696- 701. doi: 10.1136/ard.2008.092585
25. van Denderen JC, Visman IM, Nurmohamed MT, SuttorpSchulten MS, van der Horst-Bruinsma IE. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. J Rheumatol. 2014;41(9):1843-1848. doi: 10.3899/jrheum.131289
26. Lee JT, Yates WB, Rogers S, Wakefield D, McCluskey P, Lim LL. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. Br J Ophthalmol. 2018;102(12):1672-1678. doi: 10.1136/bjophthalmol-2017-311234
27. Calvo-Río V, Blanco R, Santos-Gómez M, Rubio-Romero E, Cordero-Coma M, Gallego-Flores A, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016;46(1):95-101. doi: 10.1016/j.semarthrit.2016.03.002
28. Yazgan S, Celik U, Işık M, Yeşil NK, Baki AE, Şahin H, et al. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. Int Ophthalmol. 2017;37(1):139-145. doi: 10.1007/s10792-016-0239-y
29. van Bentum RE, Heslinga SC, Nurmohamed MT, Gerards AH, Griep EN, Koehorst CBJM, et al. Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab – The GO-EASY Study. J Rheumatol. 2019;46(2):153-159. doi: 10.3899/jrheum.180312
30. Rudwaleit M, Rosenbaum JT, Landewé R, Marzo-Ortega H, Sieper J, van der Heijde D, et al. Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. Arthritis Care Res (Hoboken). 2016;68(6):838-844. doi: 10.1002/acr.22848
31. van der Horst-Bruinsma I, van Bentum R, Verbraak FD, Rath T, Rosenbaum JT, Misterska-Skora M, et al. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW. RMD Open. 2020;6(1):e001161. doi: 10.1136/rmdopen-2019-001161
32. van der Horst-Bruinsma IE, van Bentum RE, Verbraak FD, Deodhar A, Rath T, Hoepken B, et al. Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: Final 2-year results from the multicenter phase IV C-VIEW study. Ther Adv Musculoskelet Dis. 2021;13:1759720X211003803. doi: 10.1177/1759720X211003803
33. Martín-Varillas JL, Sanchez-Bilbao L, Calvo-Río V, Adán A, Hernanz I, Gallego-Flores A, et al. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: Multicentre study of 80 patients. RMD Open. 2022;8(2):e002693. doi: 10.1136/rmdopen-2022-002693
34. Deschenes J, Murray PI, Rao NA, Nussenblatt RB; International Uveitis Study Group. International Uveitis Study Group (IUSG): Clinical classification of uveitis. Ocul Immunol Inflamm. 2008;16(1):1-2. doi: 10.1080/09273940801899822
35. Rosenbaum JT. Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum. 2004;50(11):3736-3737. doi: 10.1002/art.20754
36. Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al.; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230-3236. doi: 10.1002/art.11325
37. Sieper J, Koenig A, Baumgartner S, Wishneski C, Foehl J, Vlahos B, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis. 2010;69(1):226-229. doi: 10.1136/ard.2008.103192
38. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol. 2003;87(7):925. doi: 10.1136/bjo.87.7.925
39. Cobo-Ibáñez T, del Carmen Ordóñez M, Muñoz-Fernández S, Madero-Prado R, Martín-Mola E. Do TNF-blockers reduce or induce uveitis? Rheumatology (Oxford). 2008;47(5):731-732. doi: 10.1093/rheumatology/ken091
40. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56(10):3248-3252. doi: 10.1002/art.22918
41. Raffeiner B, Ometto F, Bernardi L, Botsios C, Punzi L. Inefficacy or paradoxical effect? Uveitis in ankylosing spondylitis treated with etanercept. Case Rep Med. 2014;2014:471319. doi: 10.1155/2014/471319
42. Kwon HY, Kim YJ, Kim TH, Ahn SJ. Comparison of incidence or recurrence of anterior uveitis in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors. J Clin Med. 2024;13(3):912. doi: 10.3390/jcm13030912
43. Nasonov EL. New possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases: A focus on inhibitors of interleukin-17. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(1):68-86 (In Russ.). doi: 10.14412/1995-4484-2017-68-86
44. Nasonov EL, Korotaeva TV, Dubinina TV, Lila AM. IL-23/IL-17 inhibitors in immunoinflammatory rheumatic diseases: New horizons. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(4):400-406 (In Russ.). doi: 10.14412/1995-4484-2019-400-406
45. Dubinina TV, Gaydukova IZ, Sableva NА, Sapozhnikov KV, Sokolova VD, Tolkacheva DG. Comparative pharmacoeconomic effectiveness of interleukin-17 inhibitors for the treatment of ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(6):594-601 (In Russ.). doi: 10.47360/1995-4484-2022-594-601
46. Ruiz de Morales JMG, Puig L, Daudén E, Cañete JD, Pablos JL, Martín AO, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmun Rev. 2020;19(1):102429. doi: 10.1016/j.autrev.2019.102429
47. How Shing Koy E, Labauge P, Baillet A, Prati C, Marotte H, Pers YM. Immunomodulation with IL-17 and TNF-α in spondyloarthritis: Focus on the eye and the central nervous system. Ther Adv Musculoskelet Dis. 2021;13:1759720X211025894. doi: 10.1177/1759720X211025894
48. Jacquot R, Kodjikianc L, Chapurlat R, Sèvea P. Targeted therapies for uveitis in spondyloarthritis: A narrative review. Joint Bone Spine. 2024;(91):105697. doi: 10.1016/j.jbspin.2024.105697
49. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully human antibody to interleukin17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. doi: 10.1126/scitranslmed.3001107
50. Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL; AIN457A2208 Study Group. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122(5):939-948. doi: 10.1016/j.ophtha.2014.12.033
51. Deodhar AA, Miceli-Richard C, Baraliakos X, Marzo-Ortega H, Gladman DD, Blanco R, et al. Incidence of uveitis in secukinumab-treated patients with ankylosing spondylitis: Pooled data analysis from three phase 3 studies. ACR Open Rheumatol. 2020;2(5):294-299. doi: 10.1002/acr2.11139
52. Deodhar A, Poddubnyy D, Rahman P, Ermann J, Tomita T, Bolce R, et al. Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program. J Rheumatol. 2023;50(8):1020-1028. doi: 10.3899/jrheum.221022
53. Mazurov VI, Erdes SF, Gaydukova IZ, Dubinina TV, Pristrom AM, Kunder EV, et al. Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA. Modern Rheumatology Journal. 2020;14(4):39 49 (In Russ.). doi: 10.14412/1996-7012-2020-4-39-49
54. Godzenko AA, Agafonova EM, Dimitreva AE, Razumova IYu, Urumova MM. Course of uveitis in patients with ankylosing spondylitis during the interleukin 17 inhibitors therapy. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(5):590- 595 (In Russ.). doi: 10.47360/1995-4484-2023-590-595
55. Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, et al. Tofacitinib for the treatment of ankylosing spondylitis: A phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80(8):1004-1013. doi: 10.1136/annrheumdis-2020-219601
56. Deodhar A, van der Heijde D, Sieper J, van den Bosch F, Maksymowych WP, Kim TH, et al. Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: One-year results of a doubleblind, placebo-controlled study and open-label extension. Arthritis Rheumatol. 2022;74(1):70-80. doi: 10.1002/art.41911
57. van der Heijde D, Deodhar A, Maksymowych WP, Sieper J, van den Bosch F, Kim TH, et al. Upadacitinib in active ankylosing spondylitis: Results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD Open. 2022;8(2):e002280. doi: 10.1136/rmdopen-2022-002280
58. Baraliakos X, van der Heijde D, Sieper J, Inman RD, Kameda H, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the openlabel extension of the SELECT-AXIS 2 study. Arthritis Res Ther. 2024;26(1):197. doi: 10.1186/s13075-024-03412-8
59. Vitale A, Palacios-Olid J, Caggiano V, Ragab G, Hernández-Rodríguez J, Pelegrín L, et al. Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: A prospective cohort study from the international AIDA network registries. Front Med (Lausanne). 2024;11:1439338. doi: 10.3389/fmed.2024.1439338
60. Kraev K, Uchikov P, Hristov B, Kraeva M, Basheva-Kraeva Y, Popova-Belova S, et al. Coexistence of ankylosing spondylitis and Behçet’s disease: Successful treatment with upadacitinib. Immun Inflamm Dis. 2024;12(4):e1242. doi: 10.1002/iid3.1242
61. Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: A retrospective study. Ann Rheum Dis. 2006;65(12):1631-1634. doi: 10.1136/ard.2006.052092
62. Lie E, Lindström U, Zverkova-Sandström T, Olsen IC, Forsbladd’Elia H, Askling J, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: Results from the Swedish biologics register. Ann Rheum Dis. 2017;76(9):1515-1521. doi: 10.1136/annrheumdis-2016-210931
63. Wendling D, Joshi A, Reilly P, Jalundhwala YJ, Mittal M, Bao Y. Comparing the risk of developing uveitis in patients initiating antitumor necrosis factor therapy for ankylosing spondylitis: An analysis of a large US claims database. Curr Med Res Opin. 2014;30(12):2515-2521. doi: 10.1185/03007995.2014.969368
64. Khoury G, Morel J, Combe B, Lukas C. Occurrence of anterior uveitis in patients with spondyloarthritis treated with tumor necrosis factor inhibitors: Comparing the soluble receptor to monoclonal antibodies in a large observational cohort. Arthritis Res Ther. 2020;22(1):94. doi: 10.1186/s13075-020-02187-y
65. Lindström U, Bengtsson K, Olofsson T, Di Giuseppe D, Glintborg B, Forsblad-d’Elia H, et al. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: Does the choice of biological therapy matter? Ann Rheum Dis. 2021;80(11):1445-1452. doi: 10.1136/annrheumdis-2021-220420
66. Roche D, Badard M, Boyer L, Lafforgue P, Pham T. Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: A systematic review, a pairwise and network meta-analysis of randomized controlled trials. Arthritis Res Ther. 2021;23(1):192. doi: 10.1186/s13075-021-02549-0
67. Bechman K, Yang Z, Adas M, Nagra D, S Uğuzlar A, Russell MD, et al. Incidence of uveitis in patients with axial spondylarthritis treated with biologics or targeted synthetics: A systematic review and network meta-analysis. Arthritis Rheumatol. 2024;76(5):704-714. doi: 10.1002/art.42788
Review
For citations:
Godzenko A.A., Sheremet N.L., Nasonov E.L. Uveitis in spondyloarthritis: current possibilities of anti-inflammatory therapy. Rheumatology Science and Practice. 2025;63(2):146-157. (In Russ.) https://doi.org/10.47360/1995-4484-2025-146-157
Views:
72
Email this article 